Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria, 3052, Australia.
ACS Chem Neurosci. 2013 Apr 17;4(4):527-34. doi: 10.1021/cn400005t. Epub 2013 Feb 21.
Topographically distinct, druggable, allosteric sites may be present on all G protein-coupled receptors (GPCRs). As such, targeting these sites with synthetic small molecules offers an attractive approach to develop receptor-subtype selective chemical leads for the development of novel therapies. A crucial part of drug development is to understand the acute and chronic effects of such allosteric modulators at their corresponding GPCR target. Key regulatory processes including cell-surface delivery, endocytosis, recycling, and down-regulation tightly control the number of receptors at the surface of the cell. As many GPCR therapeutics will be administered chronically, understanding how such ligands modulate these regulatory pathways forms an essential part of the characterization of novel GPCR ligands. This is true for both orthosteric and allosteric ligands. In this Review, we summarize our current understanding of GPCR regulatory processes with a particular focus on the effects and implications of allosteric targeting of GPCRs.
在所有 G 蛋白偶联受体(GPCR)上可能存在具有不同拓扑结构的、可成药的别构结合位点。因此,用合成小分子靶向这些位点为开发新型治疗方法提供了一种有吸引力的受体亚型选择性化学先导物的方法。药物开发的一个关键部分是了解这些别构调节剂在相应的 GPCR 靶标上的急性和慢性作用。包括细胞表面递呈、内吞作用、再循环和下调在内的关键调节过程严格控制细胞表面受体的数量。由于许多 GPCR 治疗药物将被长期给药,因此了解这些配体如何调节这些调节途径是新型 GPCR 配体特征描述的重要组成部分。这对于变构配体和正位配体都是如此。在这篇综述中,我们总结了我们目前对 GPCR 调节过程的理解,特别关注了 GPCR 变构靶向的作用和影响。